A meta-analysis of gemcitabine containing chemotherapy for locally advanced and metastatic pancreatic adenocarcinoma

Journal of Hematology and Oncology

Volumn 4, Issue , 2011, Pages

  Hu, Jing ^a   Zhao, Gang ^a   Wang, Hong Xia ^a   Tang, Lei ^a   Xu, Ying Chun ^a   Ma, Yue ^a   Zhang, Feng Chun ^b  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

chemotherapy; gemcitabine; pancreatic adenocarcinoma

Indexed keywords

ANTINEOPLASTIC AGENT; AXITINIB; BEVACIZUMAB; CAMPTOTHECIN; CAPECITABINE; CETUXIMAB; CILENGITIDE; CISPLATIN; CYTOTOXIC AGENT; DOCETAXEL; EPIRUBICIN; ERLOTINIB; ETALOCIB; EXATECAN; FLUOROPYRIMIDINE; FLUOROURACIL; GEMCITABINE; IRINOTECAN; LY 600; MARIMASTAT; OXALIPLATIN; PEMETREXED; PLATINUM; TACEDINALINE; TIPIFARNIB; UNCLASSIFIED DRUG; ANTINEOPLASTIC ANTIMETABOLITE; DEOXYCYTIDINE; DRUG DERIVATIVE;

ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL PRACTICE; DRUG EFFICACY; DRUG SAFETY; HUMAN; META ANALYSIS; METASTASIS; MONOTHERAPY; OVERALL SURVIVAL; PANCREAS ADENOCARCINOMA; PROGRESSION FREE SURVIVAL; TREATMENT RESPONSE; ADENOCARCINOMA; CLINICAL TRIAL (TOPIC); PANCREAS TUMOR;

ADENOCARCINOMA; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CLINICAL TRIALS AS TOPIC; DEOXYCYTIDINE; HUMANS; PANCREATIC NEOPLASMS;

EID: 79953112266     PISSN: None     EISSN: 17568722     Source Type: Journal    
DOI: 10.1186/1756-8722-4-11     Document Type: Article

References (56)

1. Cancer of the pancreas. DB Evans JL Abbruzzese CG Willett, Cancer: Principles and Practice of Oncology Philadelphia, PA: Lippincott Williams and Wilkins, VV D Jr, Hellman S, Rosenberg SA ets, 6 2001 1126 1161
2. Dysregulation of miR-15a and miR-214 in human pancreatic cancer. XJ Zhang H Ye CW Zeng B He H Zhang YQ Chen, J Hematol Oncol 2010 3 46 10.1186/1756-8722-3-46 21106054
3. Long term survivors with metastatic pancreatic adenocarcinoma treated with gemcitabine: a retrospective analysis. BH Goulart JW Clark GY Lauwers R David G Nina M Alona Z Andrew, J Hematol Oncol 2009 2 13 10.1186/1756-8722-2-13 19291303
4. Gemcitabine-based combination for inoperable pancreatic cancer: have we made real progress? E Bria M Milella A Gelibter F Cuppone MS Pino EM Ruggeri P Carlini C Nistic E Terzoli F Cognetti D Giannarelli, Cancer 2007 110 3 525 533 10.1002/cncr.22809 17577216 (Pubitemid 47106140)
5. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. HA Burris MJ Moore J Andersen MR Green ML Rothenberg MR Modiano MC Cripps RK Portenoy AM Storniolo P Tarassoff R Nelson FA Dorr CD Stephens DD Von Hoff, J Clin Oncol 1997 15 2403 2413 9196156 (Pubitemid 27251144)
6. A randomized phase II study of gemcitabine/cisplatin, gemcitabine fixed dose rate infusion, gemcitabine/docetaxel, or gemcitabine/irinotecan in patients with metastatic pancreatic cancer (CALGB 89904). MH Kulke D Niedzwiecki MA Tempero DR Hollis RJ Mayer, J Clin Oncol 2004 22 4011
7. Gemcitabine plus capecitabine compared with gemcitabine alone in advanced pancreatic cancer: a randomized, multicenter, phase III trial of the Swiss Group for Clinical Cancer Research and the Central European Cooperative Oncology Group. R Herrmann G Bodoky T Ruhstaller B Glimelius E Bajetta J Schüller P Saletti J Bauer A Figer B Pestalozzi CH Köhne W Mingrone SM Stemmer K Tmas GV Kornek D Koeberle S Cina J Bernhard D Dietrich W Scheithauer, J Clin Oncol 2007 25 2212 221 10.1200/JCO.2006.09.0886 17538165
8. Efficacy of gemcitabine-based chemotherapy on advanced pancreatic cancer. JF Gong XD Zhang J Li LJ Di ML Jin L Shen, Ai Zheng 2007 26 890 894 17697554
9. Gemcitabine versus cisplatin, epirubicin, fluorouracil, and gemcitabine in advanced pancreatic cancer: a randomised controlled multicentre phase III trial. M Reni S Cordio C Milandri P Passoni E Bonetto C Oliani G Luppi R Nicoletti L Galli R Bordonaro A Passardi A Zerbi G Balzano L Aldrighetti C Staudacher E Villa V Di Carlo, Lancet Oncol 2005 6 369 376 10.1016/S1470- 2045(05)70175-3 15925814 (Pubitemid 40753742)
10. Phase III randomized comparison of gemcitabine versus gemcitabine plus capecitabine in patients with advanced pancreatic cancer. D Cunningham I Chau DD Stocken JW Valle D Smith W Steward PG Harper J Dunn C Tudur-Smith J West S Falk A Crellin F Adab J Thompson P Leonard J Ostrowski M Eatock W Scheithauer R Herrmann JP Neoptolemos, J Clin Oncol 2009 27 5513 5518 10.1200/JCO.2009.24.2446 19858379
11. Clinical benefit and quality of life in patients with advanced pancreatic cancer receiving gemcitabine plus capecitabine versus gemcitabine alone: a randomized multicenter phase III clinical trial - SAKK 44/00-CECOG/PAN.1.3.001. J Bernhard D Dietrich W Scheithauer D Gerber G Bodoky T Ruhstaller B Glimelius E Bajetta J Schüller P Saletti J Bauer A Figer BC Pestalozzi CH Köhne W Mingrone SM Stemmer K Tmas GV Kornek D Koeberle R Herrmann, J Clin Oncol 2008 26 3695 3701 10.1200/JCO.2007.15.6240 18669454
12. Biweekly high-dose gemcitabine alone or in combination with capecitabine in patients with metastatic pancreatic adenocarcinoma: a randomized phase II trial. W Scheithauer B Schüll H Ulrich-Pur K Schmid M Raderer K Haider W Kwasny D Depisch B Schneeweiss F Lang GV Kornek, Ann Oncol 2003 14 97 104 10.1093/annonc/mdg029 12488300 (Pubitemid 36150266)
13. Phase III study of gemcitabine in combination with fluorouracil versus gemcitabine alone in patients with advanced pancreatic carcinoma: Eastern Cooperative Oncology Group Trial E2297. JD Berlin P Catalano JP Thomas JW Kugler DG Haller AB Benson, J Clin Oncol 2002 20 3270 3275 10.1200/JCO.2002.11.149 12149301 (Pubitemid 34831525)
14. Gemcitabine with or without continuous infusion 5-FU in advanced pancreatic cancer: a randomised phase II trial of the Italian oncology group for clinical research (GOIRC). F Di Costanzo P Carlini L Doni B Massidda R Mattioli A Iop E Barletta L Moscetti F Recchia P Tralongo S Gasperoni, Br J Cancer 2005 93 185 189 10.1038/sj.bjc.6602640 15986036 (Pubitemid 41133204)
15. A randomised, prospective, multicenter, phase III trial of gemcitabine, 5-fluorouracil (5-FU), folinic acid vs. gemcitabine alone in patients with advanced pancreatic cancer. H Riess A Helm M Niedergethmann I Schmidt-Wolf M Moik C Hammer K Zippel K Weigang-Köhler M Stauch H Oettle, J Clin Oncol 2005 23 4009 10.1200/JCO.2005.08.964 15767640
16. Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: results of a GERCOR and GISCAD phase III trial. C Louvet R Labianca P Hammel G Lledo MG Zampino T André A Zaniboni M Ducreux E Aitini J Taeb R Faroux C Lepere A de Gramont GERCOR and GISCAD, J Clin Oncol 2005 23 3509 3516 10.1200/JCO.2005.06.023 15908661
17. Phase III, randomized study of gemcitabine and oxaliplatin versus gemcitabine (fixed-dose rate infusion) compared with gemcitabine (30-minute infusion) in patients with pancreatic carcinoma E6201: a trial of the Eastern Cooperative Oncology Group. E Poplin Y Feng J Berlin ML Rothenberg H Hochster E Mitchell S Alberts P O'Dwyer D Haller P Catalano D Cella AB Benson, J Clin Oncol 2009 27 3778 3785 10.1200/JCO.2008.20.9007 19581537
18. Observation of therapeutic efficacy of a biweekly regimen of Gemzar plus oxaliplatin for 30 cases with advanced pancreatic cancer. ZC Yan J Hong G Xie, Chin J Clin Oncol 2007 34 322 325
19. Randomized phase III trial of gemcitabine plus cisplatin compared with single-agent gemcitabine as first-line treatment of patients with advanced pancreatic cancer: the GIP-1 study. G Colucci R Labianca F Di Costanzo V Gebbia G Carten B Massidda E Dapretto L Manzione E Piazza M Sannicol M Ciaparrone L Cavanna F Giuliani E Maiello A Testa P Pederzoli M Falconi C Gallo M Di Maio F Perrone GOIM; GISCAD and GOIRC, J Clin Oncol 2010 28 1645 1651 10.1200/JCO.2009.25.4433 20194854
20. Gemcitabine alone or with cisplatin for the treatment of patients with locally advanced and/or metastatic pancreatic carcinoma: a prospective, randomized phase III study of the Gruppo Oncologia dell'Italia Meridionale. G Colucci F Giuliani V Gebbia M Biglietto P Rabitti G Uomo S Cigolari A Testa E Maiello M Lopez, Cancer 2002 94 902 910 10.1002/cncr.10323 11920457 (Pubitemid 34150843)
21. Gemcitabine or gemcitabine plus cisplatin for in 42 patients with locally advanced or metastatic pancreatic cancer. X Wang Q Ni M Jin Z Li Y Wu Y Zhao F Feng, Zhonghua Zhong Liu Za Zhi 2002 24 404 407 12408777
22. Randomized phase III trial of gemcitabine plus cisplatin compared with gemcitabine alone in advanced pancreatic cancer. V Heinemann D Quietzsch F Gieseler M Gonnermann H Schönekäs A Rost H Neuhaus C Haag M Clemens B Heinrich U Vehling-Kaiser M Fuchs D Fleckenstein W Gesierich D Uthgenannt H Einsele A Holstege A Hinke A Schalhorn R Wilkowski, J Clin Oncol 2006 24 3946 3952 10.1200/JCO.2005.05.1490 16921047 (Pubitemid 46630743)
23. A randomized phase 2 trial of neoadjuvant chemotherapy in resectable pancreatic cancer: gemcitabine alone versus gemcitabine combined with cisplatin. DH Palmer DD Stocken H Hewitt CE Markham AB Hassan PJ Johnson JA Buckels SR Bramhall, Ann Surg Oncol 2007 14 2088 2096 10.1245/s10434-007-9384-x 17453298 (Pubitemid 46988260)
24. A prospective randomized trial of gemcitabine alone or gemcitabine combined with cisplatin in the treatment of metastatic pancreatic cancer. CP Li Y Chao, J Clin Oncol 2004 22 140
25. Randomized phase II study of gemcitabine administered at a fixed dose rate or in combination with cisplatin, docetaxel, or irinotecan in patients with metastatic pancreatic cancer: CALGB 89904. MH Kulke MA Tempero D Niedzwiecki DR Hollis HL Kindler M Cusnir PC Enzinger SM Gorsch RM Goldberg RJ Mayer, J Clin Oncol 2009 27 5506 5512 10.1200/JCO.2009.22.1309 19858396
26. Gemcitabine in combination with cisplatin (GP) versus gemcitabine (G) alone in the treatment of locally advanced or metastatic pancreatic cancer: final results of a multicenter randomized phase II study. F Viret M Ychou D Lepille L Mineur F Navarro D Topart M Fonck J Goineau A Madroszyk-Flandin N Chouaki, J Clin Oncol 2004 22 4118
27. A multicenter phase III trial comparing irinotecan-gemcitabine (IG) with gemcitabine (G) monotherapy as first-line treatment in patients with locally advanced or metastatic pancreatic cancer. GP Stathopoulos K Syrigos G Aravantinos A Polyzos P Papakotoulas G Fountzilas A Potamianou N Ziras J Boukovinas J Varthalitis N Androulakis A Kotsakis G Samonis V Georgoulias, Br J Cancer 2006 95 587 592 10.1038/sj.bjc.6603301 16909140 (Pubitemid 44325898)
28. Irinotecan plus gemcitabine results in no survival advantage compared with gemcitabine monotherapy in patients with locally advanced or metastatic pancreatic cancer despite increased tumor response rate. CM Rocha Lima MR Green R Rotche WH Miller Jr GM Jeffrey LA Cisar A Morganti N Orlando G Gruia LL Miller, J Clin Oncol 2004 22 3776 3783 10.1200/JCO.2004.12.082 15365074 (Pubitemid 41095218)
29. Randomized phase III study of exatecan and gemcitabine compared with gemcitabine alone in untreated advanced pancreatic cancer. GK Abou-Alfa R Letourneau G Harker M Modiano H Hurwitz NS Tchekmedyian K Feit J Ackerman RL De Jager SG Eckhardt EM O'Reilly, J Clin Oncol 2006 24 4441 4447 10.1200/JCO.2006.07.0201 16983112 (Pubitemid 46630982)
30. A phase III trial of pemetrexed plus gemcitabine versus gemcitabine in patients with unresectable or metastatic pancreatic cancer. H Oettle D Richards RK Ramanathan JL van Laethem M Peeters M Fuchs A Zimmermann W John D Von Hoff M Arning HL Kindler, Ann Oncol 2005 16 1639 1645 10.1093/annonc/mdi309 16087696 (Pubitemid 41510138)
31. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. MJ Moore D Goldstein J Hamm A Figer JR Hecht S Gallinger HJ Au P Murawa D Walde RA Wolff D Campos R Lim K Ding G Clark T Voskoglou-Nomikos M Ptasynski W Parulekar National Cancer Institute of Canada Clinical Trials Group, J Clin Oncol 2007 25 1960 1966 10.1200/JCO.2006.07.9525 17452677 (Pubitemid 46972777)
32. Phase III trial of gemcitabine plus tipifarnib compared with gemcitabine plus placebo in advanced pancreatic cancer. E Van Cutsem H van de Velde P Karasek H Oettle WL Vervenne A Szawlowski P Schoffski S Post C Verslype H Neumann H Safran Y Humblet J Perez Ruixo Y Ma D Von Hoff, J Clin Oncol 2004 22 1430 1438 10.1200/JCO.2004.10.112 15084616 (Pubitemid 41103625)
33. Phase III study comparing gemcitabine plus cetuximab versus gemcitabine in patients with advanced pancreatic adenocarcinoma: Southwest Oncology Group-directed intergroup trial S0205. PA Philip J Benedetti CL Corless R Wong EM O'Reilly PJ Flynn KM Rowland JN Atkins BC Mirtsching SE Rivkin AA Khorana B Goldman CM Fenoglio-Preiser JL Abbruzzese CD Blanke, J Clin Oncol 2010 28 3605 3610 10.1200/JCO.2009.25.7550 20606093
34. Randomized double-blind phase II trial comparing gemcitabine plus LY293111 versus gemcitabine plus placebo in advanced adenocarcinoma of the pancreas. MW Saif H Oettle WL Vervenne JP Thomas G Spitzer C Visseren-Grul N Enas DA Richards, Cancer J 2009 15 339 343 10.1097/PPO.0b013e3181b36264 19672152
35. Efficacy of gemcitabine plus axitinib compared with gemcitabine alone in patients with advanced pancreatic cancer: an open-label randomised phase II study. JP Spano C Chodkiewicz J Maurel R Wong H Wasan C Barone R Létourneau E Bajetta Y Pithavala P Bycott P Trask K Liau AD Ricart S Kim O Rixe, Lancet 2008 371 2101 2108 10.1016/S0140-6736(08)60661-3 18514303
36. A double-blind placebo-controlled, randomised study comparing gemcitabine and marimastat with gemcitabine and placebo as first line therapy in patients with advanced pancreatic cancer. SR Bramhall J Schulz J Nemunaitis PD Brown M Baillet JA Buckels, Br J Cancer 2002 87 161 167 10.1038/sj.bjc.6600446 12107836
37. Gemcitabine plus bevacizumab compared with gemcitabine plus placebo in patients with advanced pancreatic cancer: phase III trial of the Cancer and Leukemia Group B (CALGB 80303). HL Kindler D Niedzwiecki D Hollis S Sutherland D Schrag H Hurwitz F Innocenti MF Mulcahy E O'Reilly TF Wozniak J Picus P Bhargava RJ Mayer RL Schilsky RM Goldberg, J Clin Oncol 2010 28 3617 3622 10.1200/JCO.2010.28.1386 20606091
38. Gemcitabine plus CI-994 offers no advantage over gemcitabine alone in the treatment of patients with advanced pancreatic cancer: results of a phase II randomized, double-blind, placebo-controlled, multicenter study. DA Richards KA Boehm DM Waterhouse DJ Wagener SS Krishnamurthi A Rosemurgy W Grove K Macdonald S Gulyas M Clark KD Dasse, Ann Oncol 2006 17 1096 1102 10.1093/annonc/mdl081 16641168 (Pubitemid 43985245)
39. A randomized multi-center phase II trial of the angiogenesis inhibitor Cilengitide (EMD 121974) and gemcitabine compared with gemcitabine alone in advanced unresectable pancreatic cancer. H Friess JM Langrehr H Oettle J Raedle M Niedergethmann C Dittrich DK Hossfeld H Stöger B Neyns P Herzog P Piedbois F Dobrowolski W Scheithauer R Hawkins F Katz P Balcke J Vermorken S van Belle N Davidson AA Esteve D Castellano J Kleeff AA Tempia-Caliera A Kovar J Nippgen, BMC Cancer 2006 6 285 10.1186/1471-2407-6-285 17156477
40. Cetuximab plus gemcitabine and cisplatin compared with gemcitabine and cisplatin alone in patients with advanced pancreatic cancer: a randomised, multicentre, phase II trial. S Cascinu R Berardi R Labianca S Siena A Falcone E Aitini S Barni F Di Costanzo E Dapretto G Tonini C Pierantoni S Artale S Rota I Floriani M Scartozzi A Zaniboni Italian Group for the Study of Digestive Tract Cancer (GISCAD), Lancet Oncol 2008 9 39 44 10.1016/S1470-2045(07)70383-2 18077217
41. A randomized, double-blind, placebo (P) controlled, multicenter phase III trial to evaluate the efficacy and safety of adding bevacizumab (B) to erlotinib (E) and gemcitabine (G) in patients (pts) with metastatic pancreatic cancer. W Vervenne J Bennouna Y Humblet S Gill MJ Moore J Van Laethem A Shang J Cosaert C Verslype E Van Cutsem, Journal of Clinical Oncology, 2008 ASCO Annual Meeting Proceedings (Post-Meeting Edition) (May 20 Supplement) 2008 26 4507
42. Capecitabine plus oxaliplatin (CapOx) versus capecitabine plus gemcitabine (CapGem) versus gemcitabine plus oxaliplatin (mGemOx): final results of a multicenter randomized phase II trial in advanced pancreatic cancer. S Boeck T Hoehler G Seipelt R Mahlberg A Wein A Hochhaus HP Boeck B Schmid E Kettner M Stauch F Lordick Y Ko M Geissler K Schoppmeyer G Kojouharoff A Golf S Neugebauer V Heinemann, Ann Oncol 2008 19 340 347 10.1093/annonc/mdm467 17962204 (Pubitemid 351201717)
43. Chemotherapy for advanced pancreatic cancer. YJ Chua D Cunningham, Best Pract Res Clin Gastroenterol 2006 20 327 348 10.1016/j.bpg.2005.10.003 16549331
44. Recent advances in gastrointestinal oncology - updates and insights from the 2009 annual meeting of the American Society of Clinical Oncology. M Javle CT Hsueh, Journal of Hematology & Oncology 2010 3 11
45. Meta-analysis of randomized trials: evaluation of benefit from gemcitabine-based combination chemotherapy applied in advanced pancreatic cancer. V Heinemann S Boeck A Hinke R Labianca C Louvet, BMC Cancer 2008 8 82 10.1186/1471-2407-8-82 18373843
46. Fluorouracil and high-dose leucovorin in previously untreated patients with advanced adenocarcinoma of the pancreas: results of a phase II trial. JA DeCaprio RJ Mayer R Gonin SG Arbuck, J Clin Oncol 1991 9 2128 2133 1960554
47. Capecitabine-based chemotherapy for metastatic colorectal cancer. W Ling J Fan Y Ma H Wang, J Cancer Res Clin Oncol 2010 20936301
48. Phase II study of oral capecitabine in patients with advanced or metastatic pancreatic cancer. TH Cartwright A Cohn JA Varkey YM Chen TP Szatrowski JV Cox JJ Schulz, J Clin Oncol 2002 20 160 164 10.1200/JCO.20.1.160 11773165 (Pubitemid 34032607)
49. Activity of cisplatin in adenocarcinoma of the pancreas. JA Wils T Kok DJ Wagener J Selleslags N Duez, Eur J Cancer 1993 29A 203 204 10.1016/0959- 8049(93)90175-F 8422283
50. Gemcitabine and cisplatin in the treatment of advanced or metastatic pancreatic cancer. V Heinemann H Wilke HG Mergenthaler M Clemens H König HJ Illiger M Arning A Schalhorn K Possinger U Fink, Ann Oncol 2000 11 1399 1403 10.1023/A:1026595525977 11142479
51. Phase II study of gemcitabine and cisplatin in the treatment of patients with advanced pancreatic carcinoma. PA Philip MM Zalupski VK Vaitkevicius P Arlauskas R Chaplen LK Heilbrun V Adsay D Weaver AF Shields, Cancer 2001 92 569 577 10.1002/1097-0142(20010801)92:3<569::AID-CNCR13563.0.CO;2-D 11505401 (Pubitemid 32735192)
52. Weekly gemcitabine and cisplatin chemotherapy: a well-tolerated but ineffective chemotherapeutic regimen in advanced pancreatic cancer patients. A report from the Italian Group for the Study of Digestive Tract Cancer (GISCAD). S Cascinu R Labianca V Catalano S Barni F Ferra GD Beretta L Frontini P Foa G Pancera D Priolo F Graziano M Mare G Catalano, Ann Oncol 2003 14 205 208 10.1093/annonc/mdg061 12562645 (Pubitemid 36305430)
53. Updates in Gastrointestinal Oncology - insights from the 2008 44th annual meeting of the American Society of Clinical Oncology. M Javle CT Hsueh, J Hematol Oncol 2009 23 2 9 10.1186/1756-8722-2-9
54. Randomized phase II trial comparing folfirinox (5FU/leucovorin [LV], irinotecan [I] and oxaliplatin [O]) vs gemcitabine (G) as first-line treatment for metastatic pancreatic adenocarcinoma (MPA). First results of the ACCORD 11 trial. M Ychou F Desseigne R Guimbaud M Ducreux O Bouché Y Bécouarn A Adenis C Montoto-Grillot E Luporsi T Conroy, J Clin Oncol 2007, ASCO Annual Meeting Proceedings Part I. Vol 25, No. 18S 20 Suppl 4516
55. Safety and clinical effectiveness of FOLFIRINOX in metastatic pancreas cancer (MPC) after first-line chemotherapy. G Breysacher O Kaatz C Lemarignier P Chiappa D Roncalez B Denis HC de Colmar, ASCO Gastrointestinal Cancers Symposium 2010 bstract No. 269
56. Quality of life assessment in advanced pancreatic adenocarcinoma: results from a phase III randomized trial. M Reni E Bonetto S Cordio P Passoni C Milandri S Cereda A Spreafico L Galli R Bordonaro C Staudacher V Di Carlo CD Johnson, Pancreatology 2006 6 454 463 10.1159/000094563 16847383 (Pubitemid 44624279)